中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
9期
1-3
,共3页
Ph染色体%急性淋巴细胞白血病%酪氨酸激酶抑制剂%造血干细胞移植
Ph染色體%急性淋巴細胞白血病%酪氨痠激酶抑製劑%造血榦細胞移植
Ph염색체%급성림파세포백혈병%락안산격매억제제%조혈간세포이식
Philadelphia chromosome%acute lymphoblastic leukemia%tyrosine kinase inhibitors%hematopoietic stem cell transplantation
成人Ph阳性急性淋巴细胞白血病预后不佳，常规化学治疗(简称化疗)生存率10%~20%，而靶向药物的应用可提高完全缓解持续时间，使更多患者能够等待造血干细胞移植。目前，临床常采用以酪氨酸激酶抑制剂( TKIs )为代表的靶向治疗进行联合化疗，作为Ph阳性急性淋巴细胞白血病（ALL）的一线治疗方案，其缓解率、生存率等均优于单纯化疗，且可提高造血干细胞移植的疗效。新型治疗方案显著改善了Ph阳性急性淋巴细胞白血病患者的预后。
成人Ph暘性急性淋巴細胞白血病預後不佳，常規化學治療(簡稱化療)生存率10%~20%，而靶嚮藥物的應用可提高完全緩解持續時間，使更多患者能夠等待造血榦細胞移植。目前，臨床常採用以酪氨痠激酶抑製劑( TKIs )為代錶的靶嚮治療進行聯閤化療，作為Ph暘性急性淋巴細胞白血病（ALL）的一線治療方案，其緩解率、生存率等均優于單純化療，且可提高造血榦細胞移植的療效。新型治療方案顯著改善瞭Ph暘性急性淋巴細胞白血病患者的預後。
성인Ph양성급성림파세포백혈병예후불가，상규화학치료(간칭화료)생존솔10%~20%，이파향약물적응용가제고완전완해지속시간，사경다환자능구등대조혈간세포이식。목전，림상상채용이락안산격매억제제( TKIs )위대표적파향치료진행연합화료，작위Ph양성급성림파세포백혈병（ALL）적일선치료방안，기완해솔、생존솔등균우우단순화료，차가제고조혈간세포이식적료효。신형치료방안현저개선료Ph양성급성림파세포백혈병환자적예후。
Adult Philadelphia chromosome-positive ( Ph+) acute lymphoblastic leukemia ( ALL ) has poor prognosis. The conventional chemotherapy for treating Ph+ALL has a survival rate of 10% -20%. The application of targeted drugs substantially improves the per-sistent duration of complete remission long-term and makes more patients to receive the hematopoietic stem cell transplantation. Now, adopting the combined chemotherapy of targeted therapy with tyrosine kinase inhibitors as representative serving as a first-line treat-ment of Ph+ALL is better than the simple chemotherapy in the response rate and survival rate, more over increases the curative effect of the hematopoietic stem cell transplantation. The new type therapeutic regimen significantly improves the prognosis of Ph+ALL.
